

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: 415129	(X2) MULTIPLE CONSTRUCTION A. Building B. Wing	(X3) DATE SURVEY COMPLETED 01/29/2025
NAME OF PROVIDER OR SUPPLIER Summit Commons Rehabilitation and Health Care Cnt		STREET ADDRESS, CITY, STATE, ZIP CODE 99 Hillside Avenue Providence, RI 02906	

For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)
<p>F 0760</p> <p>Level of Harm - Minimal harm or potential for actual harm</p> <p>Residents Affected - Few</p>	<p>Ensure that residents are free from significant medication errors.</p> <p>46539</p> <p>Based on record review and staff interviews it has been determined that the facility failed to ensure that residents are free of any significant medication errors for 1 of 1 resident reviewed for Levothyroxine (a medication used to treat hypothyroidism, an underactive thyroid), Resident ID #3.</p> <p>Findings are as follows:</p> <p>Record review revealed the resident was readmitted to the facility in January of 2025 with a diagnosis including, but not limited to, cerebral infraction (stroke).</p> <p>Record review revealed a physician's order with a start date on 1/24/2025 for Levothyroxine Sodium oral tablet, 100 micrograms (MCG) one time a day, for thyroid disease.</p> <p>Record review revealed a progress note dated 1/24/2025, which revealed that the resident's laboratory work up was reviewed by the Nurse Practitioner (NP) and a new order was obtained to decrease the Levothyroxine to 87.5 and recheck his/her labs in 6 weeks.</p> <p>Record review revealed the following physician's orders with a start date of 1/25/2025:</p> <ul style="list-style-type: none"> - Levothyroxine Sodium Oral Tablet 100 MCG one time a day for thyroid disease. - Levothyroxine Sodium Oral Tablet 87.5 MCG by mouth one time a day for hyperthyroidism. <p>Review of the January 2025 Medication Administration Record (MAR) revealed that both the Levothyroxine 87.5 MCG and Levothyroxine 100 MCG were administered together for a total dose of 187.5 MCG, on the following dates:</p> <ul style="list-style-type: none"> - 1/25/2025 - 1/26/2025 - 1/27/2025 - 1/28/2025 - 1/29/2025 <p>(continued on next page)</p>

Any deficiency statement ending with an asterisk (*) denotes a deficiency which the institution may be excused from correcting providing it is determined that other safeguards provide sufficient protection to the patients. (See instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation.

LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER REPRESENTATIVE'S SIGNATURE	TITLE	(X6) DATE
---	-------	-----------

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: 415129	(X2) MULTIPLE CONSTRUCTION A. Building B. Wing	(X3) DATE SURVEY COMPLETED 01/29/2025
NAME OF PROVIDER OR SUPPLIER Summit Commons Rehabilitation and Health Care Cnt		STREET ADDRESS, CITY, STATE, ZIP CODE 99 Hillside Avenue Providence, RI 02906	
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.			
(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)		
<p>F 0760</p> <p>Level of Harm - Minimal harm or potential for actual harm</p> <p>Residents Affected - Few</p>	<p>During a surveyor interview on 1/29/2025 at 11:28 AM, with Registered Nurse, Staff A, she acknowledged that the resident was initially on Levothyroxine 100 MCG on 1/24/2025. Additionally, she revealed that the provider reviewed the labs on 1/24/2025 and updated the order to decrease the Levothyroxine from 100 MCG to 87.5 MCG. Furthermore, she acknowledged that both the Levothyroxine 87.5 MCG and Levothyroxine 100 MCG were administered together for a total dose of 187.5 MCG, on 1/25, 1/26, 1/27, 1/28 and 1/29/2025.</p> <p>During a surveyor interview with the NP on 1/29/2025 at 12:10 PM, he revealed that he ordered the Levothyroxine to be decreased from 100 MCG to 87.5 MCG on 1/24/2025. Additionally, he acknowledged that in January 2025 MAR revealed that the resident was receiving a total dose of 187.5 MCG on 1 /25, 1/26, 1/27, 1/28 and 1/29/2025 and not the 87.5 MCG, as ordered.</p> <p>During a surveyor interview on 1/29/2025 at 12:27 PM with the Director of Nursing Services, she acknowledged that the January 2025 MAR revealed that the resident was receiving a total dose of 187.5 MCG of Levothyroxine and not the 87.5 MCG as ordered. She further acknowledged that the facility was unaware of this medication error until it was brought to their attention by the surveyor.</p>		